Life Science Investing Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 15h
Life Science Investing Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update 14 November
Life Science Investing Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases 2025 Annual Meeting 10 November
